p53 is mutated in a subset of advanced-stage prostate cancers.
p53 is mutated in a subset of advanced-stage prostate cancers.
复制标题
DOI：
--
复制
发表时间：
1993-07
期刊：
影响因子：
11.2
通讯作者：
Robert;Bookstein;D. Macgrogan;S. Hilsenbeck;F. Sharkey;D. Allred
中科院分区：
文献类型：
--
作者：
Robert;Bookstein;D. Macgrogan;S. Hilsenbeck;F. Sharkey;D. Allred
抑癌基因P53的失活导致了相当一部分人类癌症的发生和/或进展，包括乳腺癌、肺癌和结肠癌的50%。突变的P53等位基因通常在外显子5-8内含有错义的单碱基替换，并编码异常稳定的P53蛋白，这些蛋白在肿瘤细胞核中积聚到高水平。为探讨前列腺癌组织中P53基因突变的频率、类型及临床意义，采用免疫组织化学方法检测了150例前列腺癌患者的前列腺癌组织标本。19例(12.7%)肿瘤细胞核P53异常堆积(IHC)与疾病分期密切相关(69例III、IV期肿瘤中IHC+者占23%，74例0~II期肿瘤中IHC+者占4%；这些数据表明，突变的P53等位基因在早期前列腺癌中相当罕见，但在20%-25%的晚期癌症中发现，这表明P53突变在至少一部分前列腺癌的进展中发挥了作用。
Inactivation of p53, a tumor suppressor gene, contributes to the genesis and/or progression of a substantial fraction of all human cancers, including > or = 50% of breast, lung, and colon carcinomas. Mutated p53 alleles typically contain missense single-base substitutions within exons 5-8 and encode abnormally stable p53 proteins that accumulate to high levels in tumor cell nuclei. To evaluate the frequency, type, and clinical significance of p53 mutation in human prostate cancer, archival tumor material from 150 prostate cancer patients was examined by immunohistochemistry (IHC) with anti-p53 antibodies. Abnormal nuclear p53 accumulation (IHC) was observed in 19 tumors (12.7%) and was strongly related to disease stage (23% of 69 stage III or IV tumors were IHC+ versus 4% of 74 stage 0-II tumors; P A:T transitions at CpG dinucleotides. These data indicate that mutated p53 alleles are quite uncommon in early prostate cancers but are found in 20-25% of advanced cancers, suggesting a role for p53 mutation in the progression of at least a subset of prostate cancers.